Spaceflight-induced osteoporosis (SFOP) is a detrimental healthcare consequence during spaceflight. Weightlessness and ionizing radiation were main environmental factors that contribute to SFOP, especially in the manned deep space voyages. However, currently there is scarce effective method to treat SFOP. This study aims at discovering the role and mechanism of cordycepin (COR) in treating SFOP. A combined ionizing radiation and tail suspension (IR/IS) model is constructed in mice to simulate SFOP. COR injection exhibits certain dose-dependent therapeutic effects including better imageological bone index and improved histological bone regeneration in treating SFOP, which is most prominent at a dose of 20 mg/kg. A combined radiation and microgravity (R/M) model is established to treat BMSCs in vitro. 10 μM COR alleviates oxidative stress and cellular senescence of BMSCs. Through high-throughput sequencing, molecular docking and microscale thermophoresis (MST), we reveal a novel mechanism that COR interacts with p110α subunit in PI3K isoform α (PI3Kα) and inhibits PI3K kinase activity, which then regulates the PI3K/Akt/FOXO3 signalling. To elevate the bioavailability of COR in the SFOP treatment, a BMSCs-targeted delivery system that uses exosomes (Exos) modified with BMSC-affinity peptide E7 (E7-Exos) is constructed and loaded with COR. E7-Exos loaded COR reduces the dosage of COR to 5 mg/kg while enhancing the therapeutic effect than using 20 mg/kg COR alone in treating SFOP. In conclusion, COR shows promise as a potential agent in SFOP therapy.
Rationale: Nucleus pulposus (NP) fibrosis is a contributing factor to intervertebral disc degeneration (IVDD), which lacks an effective treatment. This study focuses on elucidating the role and mechanisms of the TGF-β signaling repressor SKI in NP fibrosis and exploring its therapeutic potential.
The hypoxic and high‐pressure microenvironment of the intervertebral discs poses a major challenge to the survival and therapeutic efficiency of exogenous stem cells. Therefore, improving the utilization efficiency and therapeutic effect of exogenous stem cells to delay intervertebral disc degeneration (IVDD) is of great importance. Here, hypoxic induction studies are conducted in vivo and in vitro using rat costal cartilage‐derived skeletal stem cells (SSCs) and find that hypoxia activates the cyclic guanosine monophosphate–adenosine monophosphate synthase (cGAS)/stimulator of interferon genes (STING) signaling pathway and increased reactive oxygen species (ROS) accumulation, triggering ferroptosis in SSCs through hypoxia‐inducible factor‐1 alpha‐dependent mitophagy. Progressive hypoxia preconditioning reduce STING expression and ROS accumulation, inducing SSCs differentiation into nucleus pulposus‐like cells via the Wnt signaling pathway. Considering this, a 3‐D sustained‐release culture carrier is generated by mixing SSCs with methacrylated hyaluronic acid and polydopamine nanoparticles coated with the STING inhibitor C‐176 and evaluated its inhibitory effect on IVDD. This carrier is demonstrated to inhibit the cGAS/STING pathway and prevent ROS accumulation by continuously releasing C‐176‐coated polydopamine nanoparticles, thereby reducing ferroptosis, promoting differentiation, and ultimately attenuating IVDD, suggesting its potential as a novel treatment strategy.
Lactate accumulation is a hallmark and contributing factor of intervertebral disc degeneration (IVDD), while the role of protein lactylation caused by lactate accumulation in IVDD remains unclear. Via metabolomics, single-cell RNA-sequencing analysis, and lactylation proteomics, we reveal the lactylome landscape in IVDD and identified superoxide dismutase 1 (SOD1) lactylation at lysine 123 (SOD1K123la) as crucial for IVDD aggravation. Using in vitro site-directed mutagenesis, in vivo generation of SOD1K123R mutant male rats, and in silico molecular dynamics simulations, we find that SOD1K123la alters SOD1 conformation and impairs its enzymatic activity, and induces oxidative damage, and activates p53 pathway in nucleus pulposus cells (NPCs). Notably, we identify a small molecule ZL-01 that inhibits SOD1K123la. NPC-targeted delivery of ZL-01 via collagen type II-targeted peptide-modified extracellular vesicles alleviated IVDD in male rats. Together, these findings clarify the mechanism by which SOD1K123la promotes IVDD aggravation and provide a promising therapeutic strategy for IVDD.
22 October 2024 in Journal of Orthopaedic Surgery and Research
Adjacent segment disease (ASD) is a common and serious complication that can develop in the mid- to long-term after lumbar fusion surgery. However, the underlying mechanisms of ASD are not yet fully understood. This study aimed to develop and validate a risk prediction model for ASD in patients who underwent transforaminal lumbar interbody fusion (TLIF) for lumbar degenerative diseases. Patients with lumbar degenerative disease who underwent TLIF between January 2015 and December 2016 were included in the retrospective study. The participants were divided into two groups: ASD and non-ASD. Univariate and multivariate logistic regression analyses were performed to identify factors influencing ASD after TLIF surgery. The receiver operating characteristic (ROC) curve, calibration curve, and decision curve analysis (DCA) were used to evaluate the model’s discrimination, calibration and clinical value, respectively. A total of 11.5% (59/513) of patients developed ASD. Higher BMI, lower BMD, higher disc grade, and reduced disc height were identified as independent risk factors for ASD after TLIF. The model demonstrated good discrimination in both the training and validation sets, with calibration and Hosmer-Lemeshow tests confirming accuracy, and DCA demonstrating clinical applicability. The nomogram model demonstrated promise in predicting ASD in patients who underwent TLIF, aiding clinicians in selecting the most suitable surgical approach and optimizing surgical decisions.